Hangzhou Huadong Medicine Group New Drug Research Institute

Hangzhou Huadong Medicine Group New Drug Research Institute is the primary research and development subsidiary of Huadong Medicine, a leading Chinese pharmaceutical company. The institute focuses on the discovery and development of innovative drugs in the fields of oncology, endocrinology, immunology, and nephrology. It maintains a robust pipeline featuring small molecules, monoclonal antibodies, and antibody-drug conjugates, with a significant emphasis on metabolic diseases like diabetes and obesity. Notable programs include oral GLP-1 receptor agonists and multi-target incretin mimetics. Through strategic in-licensing and internal R&D, the institute aims to bring advanced therapeutic solutions to the Chinese and global markets. It plays a critical role in Huadong Medicine's transition from a generic-focused manufacturer to an innovation-driven biopharmaceutical leader.